A device originally used to study angiogenic growth was employed by Jenkins et al. to test a novel TBK1/IKKε inhibitor on murine-derived organotypic tumour spheroids (MDOTS) and patient-derived organotypic tumour spheroids (PDOTS).61 Greater cell death of MC38 MDOTS was seen when the inhibitor was combined with anti-PD-1 treatment and was dose- and time-dependent. Here, TBK1 is linked to neoplasm.